Peptides DB
Research-centric peptide and protocol reference hub

GHRP-2 (Pralmorelin) record · updated 20h ago

Muscle & body compMetabolic & appetiteGrade B · human evidenceResearch use only
All 8 studiesJump to the evidenceCompare
What is GHRP-2 (Pralmorelin) used for?

GHRP-2 (pralmorelin) is a synthetic hexapeptide and ghrelin-receptor agonist studied as a growth hormone secretagogue, used clinically as a diagnostic agent and investigationally for GH-related research.

Primarily researched for · Muscle & body comp

Development stage

where GHRP-2 (Pralmorelin) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus. It describes the research record, not a recommendation.

Identity
NameGHRP-2 (Pralmorelin)
Chain length—
Molecular weight818 Da
FormulaC45H55N9O6
Structure typeNot established
ClassGH
Research levelWell Studied
Discovered byCurated master list · 2026

Mass and formula from PubChem CID 6918245. No verified residue count for this compound.

Pharmacology
Mechanism—
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 14, 2026. How this works →
Research stats
Total studies8
Human / animal / cellular7 / 1 / 0
Highest trial phasePreclinical
Years covered2022–2026
Latest study17d ago
Publication history
20222026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

8 rowsOpen in the library →
StudyTypeYearSummary depth
Emergence of carbapenem-resistant putative hypervirulent <i>Klebsiella pneumoniae</i> ST147 with a distinct hybrid plasmid in Türkiye.
Finding33.1% CR-hvKp among CR-Kp by 2023.
Human2026Full text read0.80
Association between overweight and growth hormone secretion in patients with non-functioning pituitary tumors.
FindingOverweight (odds ratio, 3.86; 95% confidence interval, 1.02-14.66).
Human2022Full text read0.80
Systemic infusion of exogenous ghrelin in male broiler chickens (Gallus gallus domesticus). The effect of pulse frequency, doses, and ghrelin forms on feed intake, average daily gain, corticosterone, and growth hormone concentrations.
FindingLinear decrease in FI with AG infusion, P=0.002.
Animal2022Full text read0.70
Effect of GH Deficiency Caused by Nonfunctioning Pituitary Masses on Serum C-reactive Protein Levels.
FindingPeak GH significantly and negatively predicted hs-CRP levels (β = -0.345; 95% CI, -0.533 to -0.158).
Human2023Full text read0.80
Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report.
FindingNot reported in abstract.
Human2024Full text read0.70
Combined PD-1 and CTLA-4 Blockade Increases the Risks of Multiple Pituitary Hormone Deficiency and Isolated Adrenocorticotropic Deficiency: A Prospective Study.
FindingPituitary irAEs incidence: 16/74 (21.6%) vs. 25/748 (3.3%), P<0.001
Human2025Full text read0.80
Severe hyponatremia in a mild COVID-19 patient: diagnostic challenges of SIADH and adrenal insufficiency.
FindingNot reported in abstract.
Human2025Full text read0.80
Acute Sheehan Syndrome With Distinctive Arginine Vasopressin Secretion and Magnetic Resonance Imaging Findings.
FindingNot reported in abstract.
Human2025Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching GHRP-2 (Pralmorelin) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much GHRP-2 (Pralmorelin) is discussed should be drawn from it.